UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
vTv Therapeutics (Nasdaq: VTVT), a late-stage biopharmaceutical company developing cadisegliatin for type 1 diabetes treatment, has announced its participation in two major investor conferences in September 2025.
The company will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 9 for one-on-one investor meetings, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, where management will participate in a fireside chat from 2:35 PM to 3:10 PM EST, along with individual investor meetings.
vTv Therapeutics (Nasdaq: VTVT), azienda biofarmaceutica in fase avanzata che sta sviluppando cadisegliatin per il trattamento del diabete di tipo 1, ha comunicato la sua partecipazione a due importanti conferenze per investitori a settembre 2025.
La societ脿 sar脿 presente al H.C. Wainwright 27th Annual Global Investment Conference il 9 settembre per incontri individuali con investitori, e al Morgan Stanley 23rd Annual Global Healthcare Conference il 10 settembre, dove la direzione parteciper脿 a una fireside chat dalle 14:35 alle 15:10 EST, oltre a singoli meeting con investitori.
vTv Therapeutics (Nasdaq: VTVT), compa帽铆a biofarmac茅utica en fase avanzada que desarrolla cadisegliatin para el tratamiento de la diabetes tipo 1, ha anunciado su participaci贸n en dos importantes conferencias para inversores en septiembre de 2025.
La empresa asistir谩 a la H.C. Wainwright 27th Annual Global Investment Conference el 9 de septiembre para reuniones individuales con inversores, y a la Morgan Stanley 23rd Annual Global Healthcare Conference el 10 de septiembre, donde la direcci贸n participar谩 en una fireside chat de 2:35 PM a 3:10 PM EST, adem谩s de mantener reuniones individuales con inversores.
vTv Therapeutics (Nasdaq: VTVT), 鞝�1順� 雼闺嚚氤� 旃橂鞝� 旃措敂靹戈竴毽嫶鞚� 臧滊皽 欷戩澑 頉勱赴 雼硠 氚旍澊鞓れ牅鞎届偓搿滌劀 2025雲� 9鞗旍棎 鞐措Μ電� 霊� 瓯挫潣 欤检殧 韴瀽鞛� 旖橅嵓霟办姢鞐� 彀胳劃頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
須岇偓電� 9鞗� 9鞚� H.C. Wainwright 27th Annual Global Investment Conference鞐愳劀 韴瀽鞛愳檧鞚� 鞚茧寑鞚� 氙疙寘鞚� 歆勴枆頃橁碃, 9鞗� 10鞚� Morgan Stanley 23rd Annual Global Healthcare Conference鞐愳劀電� 瓴届榿歆勳澊 氙戈淡 霃欕秬鞁滉皠(EST) 旮办 鞓ろ泟 2鞁� 35攵勲秬韯� 3鞁� 10攵勱箤歆� 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃橂┌ 臧滊硠 韴瀽鞛� 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
vTv Therapeutics (Nasdaq: VTVT), soci茅t茅 biopharmaceutique en phase avanc茅e d茅veloppant le cadisegliatin pour le traitement du diab猫te de type 1, a annonc茅 sa participation 脿 deux grandes conf茅rences investisseurs en septembre 2025.
La soci茅t茅 assistera 脿 la H.C. Wainwright 27th Annual Global Investment Conference le 9 septembre pour des rencontres individuelles avec des investisseurs, et 脿 la Morgan Stanley 23rd Annual Global Healthcare Conference le 10 septembre, o霉 la direction participera 脿 une fireside chat de 14h35 脿 15h10 EST, en plus de r茅unions individuelles avec des investisseurs.
vTv Therapeutics (Nasdaq: VTVT), ein biopharmazeutisches Unternehmen in der Sp盲tphase, das Cadisegliatin zur Behandlung von Typ-1-Diabetes entwickelt, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2025 angek眉ndigt.
Das Unternehmen wird am 9. September an der H.C. Wainwright 27th Annual Global Investment Conference f眉r Einzelgespr盲che mit Investoren teilnehmen und am 10. September an der Morgan Stanley 23rd Annual Global Healthcare Conference, wo das Management von 14:35 bis 15:10 Uhr EST an einem Fireside Chat teilnehmen wird, sowie an separaten Investorenmeetings.
- None.
- None.
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.听(Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:
| H.C. Wainwright听27th Annual Global Investment Conference | |
| Date: | Tuesday, September 9, 2025 |
| Format: | 1x1 Investor Meetings Only |
| 听 | 听 |
| Morgan Stanley 23rd Annual Global Healthcare Conference听 | |
| Date: | Wednesday, September 10, 2025 |
| Format: | Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings |
| 听 | 听 |
About听vTv听Therapeutics
vTv Therapeutics听is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv鈥檚 clinical pipeline is led by听cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at听听or follow the company on听听or听.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
FAQ
When is VTVT presenting at the Morgan Stanley Healthcare Conference 2025?
What conferences is vTv Therapeutics (VTVT) attending in September 2025?
What is vTv Therapeutics' (VTVT) main drug development focus?
What type of meetings will VTVT have at the H.C. Wainwright Conference?
